Cultivation method for producing hupenine A through in vitro induction proliferation of thallus of huperzia serrata

Abstract

The invention discloses a cultivation method for producing hupenine A through in vitro induction proliferation of thallus of huperzia serrata. The method comprises the following steps: selecting a wilding huperzia serrata plant which is healthy and has no plant disease or insect pests, and taking a new branch which grows in the current year and is 3 cm in length; producing thallus through induction, proliferating into a piece of thalline tissue block with the diameter of 3 cm, and using the two culture mediums as follows: a thalline differentiation launching culture medium and a thalline mulitiplication culture medium; and dividing and subculturing thalline. The cultivation method and a substrate formula provide essential environmental conditions to in vitro induction and proliferation ofthallus of huperzia serrata in production of hupenine A. When the method provided by the invention is used for in vitro culture of huperzia serrata, a great number of medicinal plant resources of thalline of huperzia serrata can be obtained. Significant economic values can be produced when the method is used for enlarging the scale of extracting produced medicine hupenine A (Hup-A) through in vitro culture of thalline.

Description

technical field [0001] The invention relates to a plant biotechnology, that is, a culture method for in vitro induction and proliferation, in particular to a culture method for in vitro induction and proliferation of huperzine A-producing huperzine serrata fronds. Background technique [0002] Huperzia serrata (Thunb.ex Murray) Trev., also known as Melaleuca pagoda, Serratia serrata, Snakefoot grass, etc., is a Huperzia fern in the family Huperzia, and the whole plant is used as medicine. Since it was first reported in China in 1972 that the alkaloid hupenine A (Hup-A) in this plant has the effect of relaxing striated muscles, further research has found that the alkaloid is a potent, reversible and highly selective acetylcholine. Esterase inhibitors. Under low doses of Hup-A, it has a strong inhibitory effect on acetylcholinesterase (Ach E), which significantly increases the content of acetylcholine (Ach) in the synaptic gap in the distribution area, thereby enhancing neuro...

AI Technical Summary

Problems solved by technology

Huperzine A Hup-A drug mainly comes from the whole herb of natural Huperzine serrata. Due to the special curative effect of Huperzine A, scholars at home and abroad have done a lot of work on its total synthesis, derivatives and analogs. Due to the special molecular structure of Hup-A, artificial synthesis is time-consuming, labor-intensive, and expensive. So far, almost no derivatives and analogs with better activity than natural Hup-A have been obtained. Therefore, artificially synthesized Hup-A and its analogs are far from commercialization. There is still a long way to go for production. With the arrival of an aging society, Alzheimer's disease (senile dementia) has become the fourth major disease of human beings, which directly leads to an increasing supply gap of Hup-A in the international market. The shortage of natural Melaleuca pagoda resources is highlighted

[0003] Since Huperzia serrata and other Huperzaceae plants grow in deep mountains and dense forests with special habitat conditions, it is difficult to solve the problem of large-scale artificial cultivation of Huperziaceae plants.

The Hup-A resources in Huperzia plants can be developed by adopting in vitro tissue culture of Huperzaceae plants, but due to the difficulty in explant disinfection and growth and differentiation, there is no breakthrough in its effective technology at home and abroad.

Images